MRK Related Major News
-
Merck (MRK) Tops Q1 EPS by 6c; Lowers FY13 EPS Outlook; Boosts Buyback
-
Merck (MRK) Adds $15B to Buyback Program
-
Merck & Co (MRK) Sees Q1 EPS Below the Street on Venezuelan Currency Devaluation
-
Merck (MRK) Ends '12 on High Note Despite SINGULAIR Weakness; '13 EPS Guidance Muted
-
Merck & Co., Inc. (MRK) Tops Q4 EPS by 2c; Guides In-Line
-
Merck & Co., Inc. (MRK) Tops Q3 EPS by 3c
-
Merck & Co., Inc. (MRK) Tops Q2 EPS by 4c
-
Merck & Co., Inc. (MRK) Tops Q1 EPS by 2c, Revs Light; Reaffirms Outlook
-
Merck (MRK) Guides Q1 Below the Street, Affirms FY12 Outlook
-
Merck (MRK) Shows Strong Earnings Following M&A Adjustments; Outlook Flat
-
Merck (MRK) Guides FY12 EPS
-
Merck & Co., Inc. (MRK) Tops Q4 EPS by 2c, Sales Miss Slightly
-
Merck & Co., Inc. (MRK) Tops Q3 EPS by 3c
-
Merck & Co. (MRK) Matches Q2 Views, to Cut Up to 13% of Workforce By 2015
-
Merck & Co., Inc. (MRK) Reports In-Line Q2 EPS of 95c; Raises Low End of FY11 Guidance Range
-
Merck & Co. Inc. (MRK) Tops Q1 EPS by 8c; Guides FY11 EPS
-
Merck (MRK) Posts Strong Q4; Shares Dip on FY11 EPS Forecast
-
Merck & Co. (MRK) Reports Q4 Adj-EPS of 88c, Beats by 5c; Guides FY11
-
Kenneth Frazier to Become Merck's (MRK) New CEO
-
Merck (MRK ) Income Tumbles 90% on Acquisition Charges, Federal Investigation
-
Merck (MRK) Posts Q3 non-GAAP EPS of $0.85, Tops by 3c; Raises Low-End of FY10 EPS
-
Merck (MRK) Q2 Pofits Drop 52%; EPS Tops Views But Sales Fall Flat
-
Merck (MRK) Posts Q2 EPS of $0.86, Tops by 3c; Guides FY10 EPS
-
Merck (MRK) Bests Q1 Sales and Profit Estimates
-
Merck (MRK) Tops Q1 EPS by 8c; Guides In-Line
-
Merck (MRK) Q4 Sales, Profit Rise On Schering-Plough Merger
-
Merck (MRK) Tops Q3 EPS by 8c; Guides In-Line
-
Merck & Co. (MRK) Tops Q2 EPS by 5c; Reaffirms
-
Merck (MRK) Misses Q1 EPS by 2c; Guides Roughly In-Line
-
Merck (MRK) Tops Q4 Views; Reaffirms Outlook
-
FDA Issues 2nd Complete Response Letter for Merck's (MRK) GARDASIL; Reaffirms FY09 Sales, EPS Guidance
-
Merck (MRK) Reaffirms FY08, But Guides FY09 EPS Below The Street
-
Merck (MRK) Reports Q3 Adj-EPS of $0.80, Beats by 1c; Guides FY08
-
Merck (MRK) Tops Q2 View; Will Not Provide FY08 Guidance
-
FDA Issues Response Letter Regarding Mercks (MRK) Use of GARDASIL in Women 27 to 45
-
Merck (MRK) Sinks On FDA Not Approvable Letter on CORDAPTIVE
-
Merck (MRK) Tops Q1 EPS by 4c; Reaffirms Guidance
-
Merck (MRK) and Schering-Plough (SGP) Lower After Vytorin Fails To Help Artery Damage
-
Merck (MRK) Tops Q4 Views; Guides
Back to MRK Stock Lookup
